Zeo ScientifiX Company Description

Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines.

Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, and knee osteoarthritis.

The company also provides Patient Pure X, an autologous blood-derived biologic technology, that is placed in the body for exosomes the cascade of cellular reprogramming and tissue repair.

It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential.

The company was formerly known as Organicell Regenerative Medicine, Inc. and changed its name to Zeo ScientifiX, Inc. in June 2018.

Zeo ScientifiX, Inc. was incorporated in 2011 and is headquartered in Fort Lauderdale, Florida.

Zeo ScientifiX, Inc.

Country	United States
Founded	2011
Industry	Biotechnology
Sector	Healthcare
Employees	23
CEO	Ian Bothwell

Contact Details

Address: Nova Southeastern Univ Ctr for Collabora Fort Lauderdale, Nevada 33328 United States
Phone	888 963 7881
Website	zeoscientifix.com

Stock Details

Ticker Symbol	ZEOX
Exchange	OTCMKTS
Fiscal Year	November - October
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Ian T. Bothwell	Interim Chief Executive Officer, Chief Financial Officer and Director
Dr. George C. Shapiro FACC, FACP, M.D.	Chief Medical Officer and Director
Jackie Domenech	Vice President of Operation
David Aciego	Chief Information Officer
Jill Swartz	Chief Product Officer